Effect of a <i>CYP2D6</i> polymorphism on the efficacy of donepezil in patients with Alzheimer disease

Abstract

The single nucleotide polymorphism rs1080985 in the CYP2D6 gene may influence the clinical efficacy of donepezil in patients with mild to moderate Alzheimer disease (AD). The analysis of CYP2D6 genotypes may be useful in identifying subgroups of patients with AD who have different clinical responses to donepezil.